SKF-86002 and SB-202190-Potent and selective p38 MAP kinase inhibitorsfor research purposes under agreement from GlaxoSmithKline.
References:
1. Lee, J.C., et al., Immunopharmacology, 47, 185-201 (2000).
2. Obata, T., et al., Crit. Care Med., 28, N67-77 (2000).
3. Prabhakar